NasdaqCM - Nasdaq Real Time Price USD
BioXcel Therapeutics, Inc. (BTAI)
1.6800
-0.0300
(-1.75%)
At close: 4:00:02 PM EDT
1.7386
+0.06
+(3.49%)
After hours: 6:06:28 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 1 | 2 |
| Avg. Estimate | -3.04 | -2.16 | -23.27 | -15.88 |
| Low Estimate | -3.36 | -2.24 | -23.27 | -23.76 |
| High Estimate | -2.72 | -2.08 | -23.27 | -8 |
| Year Ago EPS | -13.92 | -3.36 | -22.55 | -23.27 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 3 |
| Avg. Estimate | 350k | 400k | 3.35M | 6.67M |
| Low Estimate | 300k | 400k | 1.5M | 4.8M |
| High Estimate | 400k | 400k | 4.8M | 7.62M |
| Year Ago Sales | 582k | 1.1M | 2.27M | 3.35M |
| Sales Growth (year/est) | -39.86% | -63.77% | 48.02% | 98.93% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -11.52 | -10.99 | -7.68 | -5.14 |
| EPS Actual | -13.92 | -3.36 | -5.12 | -3.56 |
| Difference | -2.4 | 7.63 | 2.56 | 1.58 |
| Surprise % | -20.83% | 69.42% | 33.33% | 30.73% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -3.04 | -2.16 | -23.27 | -15.88 |
| 7 Days Ago | -5.28 | -4.64 | -13.49 | -8 |
| 30 Days Ago | -7.2 | -7.2 | -13.49 | -8 |
| 60 Days Ago | -7.2 | -7.2 | -18.51 | -8 |
| 90 Days Ago | -7.2 | -7.2 | -21.71 | -13.76 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | 1 |
| Up Last 30 Days | 1 | 1 | -- | 1 |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BTAI | 78.16% | 35.71% | -3.20% | 31.76% |
| S&P 500 | 7.01% | 4.85% | 8.55% | 14.15% |
Upgrades & Downgrades
| Initiated | Rodman & Renshaw: Buy | 3/19/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/30/2025 |
| Downgrade | B of A Securities: Buy to Underperform | 1/7/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 1/6/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/6/2024 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
6.03
+11.67%
BLRX BioLineRx Ltd.
2.9000
0.00%
MRSN Mersana Therapeutics, Inc.
0.3760
+15.02%
ADIL Adial Pharmaceuticals, Inc.
0.6778
+1.33%
TCRT Alaunos Therapeutics, Inc.
2.4000
+2.13%
CRIS Curis, Inc.
1.4300
+10.00%
RENB Renovaro Inc.
0.3482
-13.32%
VTYX Ventyx Biosciences, Inc.
1.1800
+4.42%
AFMD Affimed N.V.
0.7390
+5.00%
LGND Ligand Pharmaceuticals Incorporated
106.47
+1.58%